GSKGlaxoSmithKlineSigning up patients
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Multiple Myeloma · Newly Diagnosed Multiple Myeloma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 520 (planned)
- Started
- Dec 16, 2024
- Main results expected
- Apr 28, 2031
- Fully finished
- Apr 28, 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
PFS
Measured over: Up to approximately 7 years
Number of Participants Achieving MRD Negative Status
Measured over: Up to approximately 7 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06679101 · record last updated 2026-04-22 · checked 2026-11-09 15:47 UTC